CN105770148A - Preparing method for liver protecting and transaminase reducing capsules - Google Patents

Preparing method for liver protecting and transaminase reducing capsules Download PDF

Info

Publication number
CN105770148A
CN105770148A CN201610236440.6A CN201610236440A CN105770148A CN 105770148 A CN105770148 A CN 105770148A CN 201610236440 A CN201610236440 A CN 201610236440A CN 105770148 A CN105770148 A CN 105770148A
Authority
CN
China
Prior art keywords
transaminase
fine powder
hepatoprotective
capsules
manufacture method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610236440.6A
Other languages
Chinese (zh)
Inventor
李国柱
姜志戎
王心亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BAOYING TRADITIONAL CHINESE MEDICINE HOSPITAL
Original Assignee
BAOYING TRADITIONAL CHINESE MEDICINE HOSPITAL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BAOYING TRADITIONAL CHINESE MEDICINE HOSPITAL filed Critical BAOYING TRADITIONAL CHINESE MEDICINE HOSPITAL
Priority to CN201610236440.6A priority Critical patent/CN105770148A/en
Publication of CN105770148A publication Critical patent/CN105770148A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a preparing method for liver protecting and transaminase reducing capsules and relates to the technical field of Chinese patent medicine production.Firstly, herba sedi is added into water to be decocted two times, filter liquid is combined, the filter liquid is concentrated to form clear paste, then, radix astragali fine powder, fructus schizandrae fine powder, radix glycyrrhiza fine powder and the clear paste are stirred evenly, the mixture is dried and then smashed, and finally, the powder is packaged into capsules.The technology is adopted to prepare the capsules, by the adoption of compatibility of medicines for synergism, the human immunity function can be enhanced, exogenous evil virus invasion can be resisted, liver cells are protected through various approaches, and transaminase is reduced.Compared with a single medicine, the treatment effect of the capsules is obviously improved.

Description

The manufacture method of hepatoprotective transaminase lowering capsule
Technical field
The present invention relates to the production technical field of Chinese patent medicine.
Background technology
Finding in clinical examination, the high patient of transaminase is comparatively general, how by poisoning intrusion, drugs damage, drink, tired etc. cause.
The medicine of existing market the liver protecting and ALT lowering mostly is chemical drugs, and Liver and kidney is had certain side effect by long-term taking.
The Radix Astragali: tonifying Qi and lifting yang, benefit defend consolidating superficial resistance, promoting pus discharge and tissue regeneration strengthening, inducing diuresis to remove edema.For deficiency of spleen-QI and stomach-QI, insufficiency of vital energy and blood, body void hyperhidrosis.
Herba Sedi: dampness removing jaundice eliminating, heat-clearing and toxic substances removing.For jaundice due to damp-heat, dysuria, carbuncle skin infection.
Fructus Schisandrae Chinensis: astringe the lung, nourishing kidney, promote the production of body fluid, receive antiperspirant, arresting seminal emission.Breathing with cough for the deficiency of the lung, xerostomia is made thirsty, spontaneous perspiration, night sweat, impairment caused by overstrain weakness and emaciation, emission, chronic diarrhea chronic dysentery.
Radix Glycyrrhizae: QI invigorating invigorating middle warmer；Relieving spasm to stop pain；Nourishing the lung to arrest cough；Eliminating fire and detoxication；Coordinating the actions of various ingredients in a prescription.Main asthenia lack of appetite；Leanness yellowish complexion；Shortness of breath and palpitation；Stomachache loose stool；Extremity contraction urgency pain；Hysteria；Cough and asthma；Laryngopharynx swelling and pain；Ulcerative carbuncle swells and ache；Infantile carbuncle；And medicine, alimentary toxicosis.
Modern medicine study is thought: the Radix Astragali has enhancing human body immunity function, hepatoprotective effect.Herba Sedi has reduction glutamate pyruvate transaminase effect, can be used for the activeness of acute hepatitis, chronic persistent hepatitis, chronic hepatitis.Fructus Schisandrae Chinensis has obvious hepatoprotective effect, and transaminase can be suppressed to discharge, and strengthens liver detoxification ability.Containing effective ingredient such as glycyrrhizic acids in Radix Glycyrrhizae, there is hepatoprotective effect, and stop cell entry hepatocyte by changing permeability of cell membrane, reach the effect of antiviral, be attached in hepatocyte suppress hepatitis B virus additionally, it can also be concentrated.
Summary of the invention
The present invention seeks to propose the production method of a kind of hepatoprotective transaminase lowering capsule having no side effect.
The technical scheme is that: first by Herba Sedi boiling twice, merge filtered solution, filtered solution concentration being formed clear paste, then Radix Astragali fine powder, Fructus Schisandrae Chinensis fine powder, Radix Glycyrrhizae fine powder is mixed thoroughly with clear paste, drying is pulverized again, finally loads capsule.
Radix Astragali invigorating QI to consolidate the body surface resistance, strengthening body resistance, astragaloside can protect the liver again, and the present invention it can be used as monarch drug.
Herba Sedi specially controls various hepatitis, has significant curative effect to reducing serum glutamic pyruvic transminase (ALT), hepatocyte injury is had protective effect.
Deoxyschizandrin in Chemical composition of Wuweizi, B prime can protect hepatocyte, reduce transaminase, and the present invention it can be used as ministerial drug.
Glycyrrhizic acid in Radix Glycyrrhizae has the liver protecting and ALT lowering effect, and the present invention it can be used as adjuvant.
Make capsule by present invention process, adopt above compatibility can strengthen immune function of human body for collaborative altogether, resist exopathogen poisoning intrusion, by multiple by way of protection hepatocyte, reduce transaminase.Substantially increase than single medicinal material therapeutic effect.Finished product of the present invention can be granule, pill or powder.
This product is pure Chinese medicinal preparation, can long-term taking, preparation is simple, and determined curative effect carries taking convenience.
Further, the mass ratio that feeds intake of Herba Sedi of the present invention, the Radix Astragali, Fructus Schisandrae Chinensis and Radix Glycyrrhizae is 2.5～3.5: 2～3: 2.5～3.5: 2～3.Due to the place of production of medical material, period of storage, drug effect is had certain impact, can suitably adjust consumption, so having formulated certain amount ranges.It addition, each medicine modern study achievement is determined this medication ratio according to Chinese medicine monarch theory and combining.More more notable than other proportion compatibilities through test curative effect.
Described dry temperature conditions is 100 DEG C, dry 6 hours.Medical material is had certain sterilization functions, does not also affect the reservation of the active component of medicine simultaneously by 100 DEG C, within dry 6 hours, ensures that medicated powder water content is below 9%, it is simple to fill, preservation.
Herba Sedi is 1: 8 with the first mass ratio that feeds intake decocting water, and first time decocting time is 2 hours.Herba Sedi is grass class Chinese medicine, and water absorption is big, with the water of 8 times amount, within 2 hours, is easy to fully decoct out effective ingredient.
Herba Sedi is 1: 6 with the second mass ratio that feeds intake decocting water, and second time decocting time is 1 hour.For ease of abundant effective component extracting, Herba Sedi being decocted twice, because being that second time decocts, water consumption and time suitably shorten, and improve efficiency.
The density of described clear paste is 1.16～1.18g/cm3.This is to decoction liquor quality control, it is ensured that the optimum efficiency of decoction liquor.
Detailed description of the invention
One, preparation technology:
Weigh respectively: the Radix Astragali 2～3kg, Herba Sedi 2.5～3.5kg, Fructus Schisandrae Chinensis 2.5～3.5kg, Radix Glycyrrhizae 2～3kg.
The Radix Astragali, Fructus Schisandrae Chinensis and Radix Glycyrrhizae are respectively crushed into fine powder.
By Herba Sedi boiling twice, first time adds 8 times amount decocting 2 hours, and second time adds 6 times amount decocting 1 hour, filters respectively, merging filtrate, then the filtrate concentration that will merge, and acquirement relative density is 1.16～1.18g/cm3Clear paste.
The Radix Astragali of fine-powdered, Fructus Schisandrae Chinensis and Radix Glycyrrhizae and clear paste are mixed thoroughly, is placed under 100 DEG C of conditions dry 6 hours, then pulverizes, then mix, load capsule by 0.25g/ grain.
Two, use:
1, clinical case result of use:
Clinical in 216 example glutamate pyruvate transaminase (ALT), glutamic oxaloacetic transaminase, GOT (AST), alkali phosphatase (ALP), the treatment of glutamyl transferase (GGT) patients with abnormal.18～75 years old age, individual event exception person 112 example, more than 2 exception person 104 examples.
Therapeutic Method: oral this product, every day 3 times, each 6,30 days be a course for the treatment of.One course for the treatment of of the shortest person course for the treatment of, 3 courses for the treatment of of most elder.
Efficacy evaluation:
Excellent: four enzymes are all become a full member often；
Good: 2-3 item enzyme transfers to normally；
Can: there is 1 enzyme to transfer to normally；
Difference: all do not transfer to normal or only have decline.
Therapeutic outcome: this organizes 216 examples, excellent 86 examples, accounts for 39.8%；Good 93 examples, account for 43.1%；Can 31 examples, account for 14.4%；Differ from 4 examples, account for 1.8%.Acceptance rate accounts for 82%, and total effective rate is 98.1%.
2, different formula is adopted to carry out contrast experiment:
In following table:
Experimental group 1: without the Radix Astragali in side, 60 cases are carried out clinical trial.
Experimental group 2: without Herba Sedi in side, 60 cases are carried out clinical trial.
Experimental group 3: without Radix Glycyrrhizae in side, 60 cases are carried out clinical trial.
60 cases are carried out clinical trial by experimental group 4: product of the present invention.
60 cases are carried out clinical trial by matched group: the liver-protecting tablet that Heilongjiang Kuihua Yaoye Co.Ltd Co., Ltd produces.Because Heilongjiang Kuihua Yaoye Co.Ltd Co., Ltd produce liver-protecting tablet can not long-term taking, therefore only take 60 days as comparison.
Result is shown in following table:
As seen from the above table: the capsule that present invention process is made has clear superiority.

Claims (6)

1. the manufacture method of hepatoprotective transaminase lowering capsule, it is characterised in that first by Herba Sedi boiling twice, merges filtered solution, filtered solution concentration is formed clear paste, Radix Astragali fine powder, Fructus Schisandrae Chinensis fine powder, Radix Glycyrrhizae fine powder being mixed thoroughly with clear paste, drying is pulverized again, finally loads capsule again.
2. the manufacture method of hepatoprotective transaminase lowering capsule according to claim 1, it is characterised in that the mass ratio that feeds intake of described Herba Sedi, the Radix Astragali, Fructus Schisandrae Chinensis and Radix Glycyrrhizae is 2.5～3.5: 2～3: 2.5～3.5: 2～3.
3. the manufacture method of hepatoprotective transaminase lowering capsule according to claim 1, it is characterised in that described dry temperature conditions is 100 DEG C, dry 6 hours.
4. the manufacture method of hepatoprotective transaminase lowering capsule according to claim 1, it is characterised in that Herba Sedi is 1: 8 with the first mass ratio that feeds intake decocting water, first time decocting time is 2 hours.
5. the manufacture method of hepatoprotective transaminase lowering capsule according to claim 4, it is characterised in that Herba Sedi is 1: 6 with the second mass ratio that feeds intake decocting water, second time decocting time is 1 hour.
6. the manufacture method of hepatoprotective transaminase lowering capsule according to claim 1, it is characterised in that the density of described clear paste is 1.16～1.18g/cm3。
CN201610236440.6A 2016-04-18 2016-04-18 Preparing method for liver protecting and transaminase reducing capsules Pending CN105770148A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610236440.6A CN105770148A (en) 2016-04-18 2016-04-18 Preparing method for liver protecting and transaminase reducing capsules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610236440.6A CN105770148A (en) 2016-04-18 2016-04-18 Preparing method for liver protecting and transaminase reducing capsules

Publications (1)

Publication Number Publication Date
CN105770148A true CN105770148A (en) 2016-07-20

Family

ID=56397687

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610236440.6A Pending CN105770148A (en) 2016-04-18 2016-04-18 Preparing method for liver protecting and transaminase reducing capsules

Country Status (1)

Country Link
CN (1) CN105770148A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107982416A (en) * 2017-12-11 2018-05-04 无锡盛雅生物科技有限公司佛山分公司 A kind of preparation process of protect liver microballoon

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
湖南医药工业研究所技术情报研究室: "《国内中草药防治病毒性肝炎研究概况》", 31 May 1976, 湖南医药工业研究所技术情报研究室 *
王月华等: ""益肝平颗粒主要药效学研究"", 《南京中医药大学学报》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107982416A (en) * 2017-12-11 2018-05-04 无锡盛雅生物科技有限公司佛山分公司 A kind of preparation process of protect liver microballoon

Similar Documents

Publication Publication Date Title
CN102048959B (en) Dendrobium candidum compound preparation capable of regulating function of human body in two-way manner and preparation method thereof
CN101596230B (en) Medicinal composition for treating hepatopathy
CN101401915A (en) Chinese medicine formulation for treating cancer and preparation method thereof
CN112569305A (en) Mushroom compound polysaccharide composition for improving immunity and preparation method thereof
CN101199596A (en) Chinese medicine compound of alleviating cancer release, chemo-treatment toxicum side effect and preparing method thereof
CN102085235A (en) Composition having immunity-enhancing effect
CN101856487A (en) Chinese medicament for treating insomnia
CN103705578B (en) There is blood fat reducing and Chinese medicine preparation suppressing blood glucose rising effect and preparation method thereof
CN101347543A (en) Chinese medicine compound and preparation method thereof
CN105770148A (en) Preparing method for liver protecting and transaminase reducing capsules
CN102078600B (en) Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same
CN104225295A (en) Composition for improving sleep, and preparation method and application thereof
CN106038702B (en) Antifatigue composition and its preparation method and application
CN106511915A (en) Applications of compound traditional Chinese medicinal composition in preparing medicines for inhibiting skin melanoma lung metastasis
CN102631492B (en) Chinese medicinal composition for improving immunity and resisting fatigue
CN111700974A (en) Dendrobium yin nourishing and blood sugar reducing pill and preparation method thereof
CN102716448A (en) Chinese patent medicine and TCM decoction capable of effectively curing nausea and vomiting
CN100528209C (en) Preparation method of traditional Chinese medicine preparation having functions of invigorating qi and yin and blood and releasing poison
CN102631486B (en) Health care composition
CN102008520A (en) Drug for preventing and treating chronic mountain sickness and preparation method thereof
CN102266417B (en) Chinese medicine for treating acquired immune deficiency syndrome and preparation method and administration method thereof
CN102526470B (en) Medicinal composition for treating primary hypertension
CN108619394A (en) A kind of composition of strengthen immunity and application thereof
CN101224295A (en) Chinese traditional medicine compounds for treating digestive system tumor and preparing method thereof
CN106038994A (en) Food medicine for assisting in blood glucose reducing and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160720